Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sheryl McCoy"'
Autor:
James H. Doroshow, Patrick W. Cobb, James L. Abbruzzese, John S. Macdonald, Sheryl McCoy, Taral Patel, Brian F. Issell, Kathleen J. Yost
Publikováno v:
Investigational New Drugs. 24:537-542
From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401. Of these 65 patient
Autor:
Michael Tanaka, James L. Abbruzzese, Heinz-Josef Lenz, Marcus A. Neubauer, Sheryl McCoy, John S. Macdonald, Shaker R. Dakhil, Saul E. Rivkin, Robert P. Whitehead
Publikováno v:
Investigational New Drugs. 24:335-341
Purpose: The purpose of this Phase II multi-institutional trial was to determine the efficacy and toxicity of R115777 in previously untreated patients with metastatic colorectal carcinoma. Patients and methods: Patients were required to have histolog
Autor:
Novello, Silvia, Scagliotti, Giorgio Vittorio, Oleksandr, Sydorenko, Ihor, Vynnychenko, Constantin, Volovat, Claus Peter Schneider, Fiona, Blackhall, Sheryl, Mccoy, Yong jiang Hei, Spigel, David R.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______970::1495df8c6017c255bb669f8fd5f8f2c3
http://hdl.handle.net/2318/150433
http://hdl.handle.net/2318/150433
Autor:
James L. Wade, James L. Abbruzzese, Sheryl McCoy, John S. Macdonald, Jeffrey K. Giguere, Robert P. Whitehead, Syma Iqbal
Publikováno v:
Investigational New Drugs. 23:485-487
Ninety per cent of pancreatic adenocarcinomas (PC) contain mutations of the K-Ras proto-oncogene resulting in constitutively activated Ras protein. A critical step in Ras activation is farnesylation of Ras protein. Farnesyl transferase inhibitors are
Autor:
Yong Jiang Hei, David R. Spigel, Keunchil Park, Rinat Galiulin, Natividad Martinez Banaclocha, Francesco Galimi, Oleksandr Sydorenko, Kaoru Kubota, Fiona H Blackhall, Robert Pirker, Giorgio V. Scagliotti, Ihor Vynnychenko, Mircea Dediu, Sheryl McCoy, Bin Yao, Yukito Ichinose, Tudor Ciuleanu, Zsolt Papai-Szekely
Purpose We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) vers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222c454ddddee6e7cb2f53863d935a4f
http://hdl.handle.net/2318/118283
http://hdl.handle.net/2318/118283
Autor:
Charles S. Fuchs, Sheryl McCoy, Jacqueline Benedetti, Peter C. Enzinger, Scott A. Hundahl, Jeffrey A. Meyerhardt, John S. Macdonald
Some, but not all, studies using registry data have suggested a small but significant long-term survival advantage following a curative surgical resection of gastric cancer at hospitals where the volume of such surgeries is high. However, because suc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0704e69d962ed7fbd81eb160d1aa0cd2
https://europepmc.org/articles/PMC1877009/
https://europepmc.org/articles/PMC1877009/
Autor:
Jiang Wang, Tomislav Dragovich, Amanda F. Baker, Cecilia M. Fenoglio-Preiser, Jacqueline Benedetti, James L. Abbruzzese, Charles D. Blanke, Christopher B. Hackett, Sheryl McCoy, Ken S. Zaner, Susan G. Urba
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(30)
Purpose A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: gastroesophageal junction (GEJ)/cardia
Autor:
James L. Abbruzzese, Sheryl McCoy, Shaker R. Dakhil, Kathleen J. Yost, Jorge C. Paradelo, David R. Gandara, Stephen K. Williamson, James N. Atkins, Charles D. Blanke
Publikováno v:
American journal of clinical oncology. 29(2)
Metastatic esophageal carcinoma is an incurable disease with median survival duration of 6 to 8 months. Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patients wi
Autor:
Carol M. Moinpour, Patricia A. Ganz, Gretchen S. Gatti, Sheryl McCoy, Ellen R. Gaynor, Donna K. Pauler, Alice B. Kornblith, Richard I. Fisher, Oliver W. Press, Stanley P. Balcerzak, Harry P. Erba
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(18)
Purpose: We describe the short and intermediate-term quality-of-life (QOL) outcomes in patients treated on a randomized clinical trial in early-stage Hodgkin’s disease (Southwest Oncology Group [SWOG] 9133) comparing subtotal lymphoid irradiation (
Publikováno v:
Statistics in medicine. 22(5)
Analyses of longitudinal quality of life (QOL) for patients with advanced stage disease are frequently plagued by problems of non-random drop-out attributable to deteriorating health and/or death. As an example, Moinpour et al. cite specific challeng